Galvus Met 50mg/500mg Tablet is a combination oral medication containing Vildagliptin 50mg and Metformin 500mg, primarily prescribed for the management of type 2 diabetes mellitus. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's ability to regulate blood sugar by increasing insulin secretion and decreasing glucagon levels in response to meals. Metformin, a biguanide, works by reducing hepatic glucose production and improving insulin sensitivity, thereby helping to control blood glucose levels effectively. This combination is particularly beneficial for patients who have not achieved adequate glycemic control with Metformin alone. Galvus Met helps in maintaining stable blood sugar levels, reducing the risk of diabetes-related complications such as neuropathy, nephropathy, and retinopathy. It is usually taken orally, with meals, to minimize gastrointestinal side effects commonly associated with Metformin. Patients are advised to follow their healthcare provider’s instructions regarding dosage and lifestyle modifications, including diet and exercise, to optimize treatment outcomes. Regular monitoring of blood glucose and kidney function is recommended during therapy. Galvus Met is not suitable for patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment.